All News
AAOS Clinical Practice Guideline for Knee Osteoarthritis
The American Academy of Orthopaedic Surgeons has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of the 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function.
Read ArticleObesity Rates Rise During the Pandemic
New data from the Centers for Disease Control and Prevention shows that obesity rates have risen in the USA during the pandemic. Sixteen states have obesity rates of 35% or higher - that's four more than last year, adding Delaware, Iowa, Ohio and Texas to the list.
Read ArticleRheumNow Podcast – Jack of All Subspecialties (10.1.2021)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleCDC Advises COVID-19 Vaccines for Pregnant Women
Today, CDC issued an urgent health advisory to increase COVID-19 vaccination among people who are pregnant, recently pregnant (including those who are lactating), who are trying to become pregnant now, or who might become pregnant in the future to prevent serious illness, deaths, and adverse
Read ArticleGout Flare and Treatment Studies Lacking in Severe Chronic Kidney Disease
Gout is a common comorbidity amongst those with chronic kidney disease (CKD), with the added challenge of choosing best therapies in the setting of declining renal function. A systematic literature review notes significant deficiencies regarding the efficacy and safety outcom
Read ArticleStarting Febuxostat During an Acute Gout Flare
A randomized controlled trial in gout patients has shown that starting febuxostat during an acute gout flare was without ill-effects and did not prolong the gouty attack.
Read ArticleIs Acetaminophen Potentially Hazardous in Pregnancy?
A consensus report from a multinational group of 91 scientists, clinicians and public health professionals alarmed the medical world last week as they suggest the use of acetaminophen (paracetamol) during pregnancy may have hazardous developmental effects on the fetus.
Read ArticleNo Recurrent Cancer Risk With Biologic Treatment of RA
Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.
Read ArticleRheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.
Read ArticleGuselkumab Treats Axial Disease in Psoriatic Arthritis
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.
Read Article11 Drugs That Cause Arthritis
This is the #1 question I get from new consults: “How did I get arthritis?”
But as the aching are asking, they are really thinking these joint complaints must be due to something.
IL-6 Inhibition in Refractory Systemic Sclerosis
A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype.
Read ArticleTocilizumab and Drug Shortage Headaches
Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.
Read ArticleLinks:
RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)
Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.
Read ArticleACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule
In comments submitted to the Centers for Medicare and Medicaid Services (CMS), the American College of Rheumatology (ACR) shared its perspective on the CY 2022 Medicare Physician Fee Schedule and Quality Payment Program proposed rule.
Canakinumab Use in Periodic Febrile Disorders
A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.
Read ArticleDifferent Regimens but Equal Outcomes in Polyarticular JIA
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.
Read ArticleHigh Drug Switching and Low Persistence in Rheumatoid Arthritis
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
Read ArticleACR Comments on JAK Inhibitors and FDA Announcement
Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.
Read Article